WO2024116127 - VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4
National phase entry is expected:
Publication Number
WO/2024/116127
Publication Date
06.06.2024
International Application No.
PCT/IB2023/062098
International Filing Date
30.11.2023
Title **
[English]
VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4
[French]
VENGLUSTAT EN COMBINAISON AVEC UN INHIBITEUR FORT OU MODÉRÉ DE CYP3A4
Applicants **
GENZYME CORPORATION
450 Water Street
Cambridge, Massachusetts 02141, US
Inventors
CRAWFORD, Nigel Patrick Somerville
c/o Sanofi, Patent Department
450 Water Street
Cambridge, Massachusetts 02141, US
LI, Li
c/o Sanofi, Patent Department
Tower III, Kerry Center
1228 Yan'an Road
Jing An District
Shanghai 200040, CN
SHARMA, Jyoti
c/o Sanofi, Patent Department
450 Water Street
Cambridge, Massachusetts 02141, US
ZHANG, Yan-Yan
c/o Sanofi, Patent Department
Tower III, Kerry Center
1228 Yan'an Road
Jing An District
Shanghai 200040, CN
Priority Data
63/429,338
01.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1886 | |
| EPO | Filing, Examination | 9401 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 9910 |
Total: 22361 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are methods in which patients are administered venglustat in combination with inhibitors of cytochrome CYP3A4. The methods may involve making specific adjustments to the venglustat dosage in order to optimise the clinical response of the patient.[French]
L'invention concerne des procédés dans lesquels des patients se voient administrer du venglustat en combinaison avec des inhibiteurs du cytochrome CYP3A4. Les procédés peuvent impliquer la réalisation d'ajustements spécifiques à la dose de venglustat afin d'optimiser la réponse clinique du patient.